Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1 8Phase 3 5Phase 1/2 5

Status

Active not recruiting 5Recruiting 3Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Gynecologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2Recurrence 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Endometrial Neoplasms 1

Interventions

Carboplatin 106Cisplatin 97Paclitaxel 78pembrolizumab 69Gemcitabine 59Pemetrexed 49Cyclophosphamide 46Docetaxel 45Dexamethasone 45durvalumab 44Capecitabine 44Radiotherapy 40Nivolumab 37Lenalidomide 37Specimen Handling 36Doxorubicin 36Rituximab 34Oxaliplatin 34Bevacizumab 33Magnetic Resonance Spectroscopy 32Fluorouracil 32atezolizumab 29Etoposide 29Vincristine 26Radiation 26Leucovorin 26Letrozole 24Bortezomib 24Fulvestrant 23Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × dostarlimab × Clear all
NCT03602859 2025-12-31

FIRST

Tesaro, Inc.

Phase 3 Active not recruiting
1,400 enrolled 18 charts
Gynecologic

Ovarian Neoplasms

NCT05201547 2025-12-04

DOMENICA

ARCAGY/ GINECO GROUP

Phase 3 Active not recruiting
260 enrolled
Gynecologic

Neoplasm Metastasis, Endometrial Neoplasms

NCT04655976 2025-09-26

COSTAR Lung

GlaxoSmithKline

Phase 3 Active not recruiting
758 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06472076 2025-09-10

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

GlaxoSmithKline

Phase 3 Active not recruiting
88 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting
785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡